Peaches Biotech publishes positive in vivo results of its drug PRS CK STORM
Peaches Biotech publishes positive in vivo results of its drug PRS CK STORM of its drug PRS CK STORM against the cytokine storm associated with infectious processes, including COVID-19. These results, published in the journal Biomedicines, refer to the in vivo...
Peaches Biotech deciphers communication language between immune cells and other tissues
Peaches Biotech publishes in Biomolecules its work on how the immune system communicates with tissues damaged or attacked by viruses or bacteria. This breakthrough opens a way to find new drugs, of biological origin, of great importance in advanced therapies such as...
“Our approach is very mindful of the specificity of each tumor in each patient.”
The online healthcare newspaper Con Salud has interviewed our research associate, Dr. Senthil Muthuswamy, Director of Translational Research at the Beth Israel Deaconess Hospital Cancer Center in Boston, and published in detail what the platform consists of. opT of...
Europe Next 2050
On February 24, we participated in the meeting Europe Next 2050 inaugurated by the Secretary of State for Trade, Xiana Mèndez, where we contributed with our vision of biotechnology at the discussion table on the Industry 4.0 . Our CEO and founder, Juan Carlos...